Kelly Gold
Known title: Chief Financial OfficerCIK: 0002033333
Kelly Gold's purchase track record
Kelly Gold has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/31/2026 | CAMP | $40K | pending | pending | — |
| 8/3/2026 | CAMP | $11K | pending | pending | — |
| 9/11/2025 | CAMP | $10K | +116.2% | +93.5% | +1.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| CAMP | ▲ Buy | Open Market | 10,000 | $40K | 8/31/2026 | View on chart |
| CAMP | ▲ Buy | Open Market | 6,551 | $11K | 8/3/2026 | View on chart |
| CAMP | ▲ Buy | Open Market | 6,060 | $10K | 9/11/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
CAMP4 Therapeutics Targets Q4 Start for ASCEND Trial
CAMP4 Therapeutics announced plans to begin the ASCEND trial for its SYNGAP1 therapy, CMP-002, in the fourth quarter. This clinical milestone follows an analyst day where the company shared updates with investors. Chardan Capital recently lowered its price target to $6, reflecting a more conservative outlook despite maintaining a positive stance.
CAMP4 Therapeutics Targets Q4 Start for ASCEND Trial. CAMP4 Therapeutics announced plans to begin the ASCEND trial for its SYNGAP1 therapy, CMP-002, in the fourth quarter. This clinical milestone follows an analyst day where the company shared updates with investors. Chardan Capital recently lowered its price target to $6, reflecting a more conservative outlook despite maintaining a positive stance.